Recent Clinical Trials 

Retina Research Center is currently participating in 20 Phase I-III clinical trials, 12 of which are currently enrolling, including:
Wet Age-Related Macular Degeneration
Non-proliferative Diabetic Retinopathy
Diabetic Macular Edema
Dry AMD - Geographic Atrophy
Macular Telangiectasia
(posted March 2019)


Retina Research Center Enrolling in MacTel Clinical Trial

Neurotech and Lowry Medical Research Institute (LMRI) are collaborating on a natural history registry study and an interventional Phase III program, NT-501, in patients with MacTel. Neurotech is a privately held biotech company focused on development of therapies in eye disease utilizing their patented genetically engineered ocular implant, Encapsulated Cell Therapy (ECT). LMRI is a non-profit research institute founded by Frank Lowy, a real estate developer whose son was diagnosed with MacTel. LMRI initiated a registry study in 2005 to gather a database of patients with MacTel Type II. This database is used to document clinical and structural features of MacTel, determine if there is a genetic component to the disease and aide in identifying potential consenting patients for treatments in clinical trials such as the Neurotech Phase III NT-501 trial. Retina Research Center is the only site in central Texas participating in both studies. The physicians at Retina Research Center, Dr. Berger, Dr. Jhaveri, Dr. Chexal and Dr. Jonna, will be hosting a recruitment dinner on March 12, 2019 at Fleming’s Steakhouse at the Domain, 11600 Century Oaks Terrace, Austin, TX at 6:30PM. Please contact Ivana Gunderson at [email protected] for more information on clinical trials and the dinner.

If you would like your clinical trials added to the TOA website, contact Rachael Reed at [email protected] Listings will be removed upon request or after one year.